688 results about "A lipoprotein" patented technology

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.

The invention provides a preparation method of cereal fermentation broth postbiotics and application of the cereal fermentation broth postbiotics in improvement of systemic chronic inflammation and reduction of cholesterol and low-density lipoprotein, and belongs to the technical field of fermentation engineering. The invention provides a preparation method of cereal fermentation broth metabiotics, which is characterized in that mixed cereals are used as raw materials, anaerobic fermentation is carried out by using compound enzymes and various bacteria, and polysaccharides and proteins in the cereal raw materials can be quickly converted into functional small molecular substances, such as polypeptides, total phenols and total flavonoids. The cereal fermentation broth metagen can inhibit secretion of a macrophage proinflammatory medium, inhibit generation of inflammatory factors of liver, heart and intestinal tissues, and improve activation of adipose tissue macrophages related to body inflammation. After the cereal fermentation liquor is subjected to post-biogen treatment, glucose and lipid metabolism disorder can be effectively improved, liver function damage can be relieved, and the intestinal barrier function can be effectively improved.

The invention provides a recombinant vector for expressing LPL, a recombinant bacterium and an LPL production method, and belongs to the technical field of gene engineering. The invention provides a recombinant expression vector of Pseudomonas aeruginosa lipoprotein lipase LPL, wherein an LPL coding gene is derived from Pseudomonas aeruginosa. The recombinant expression vector is introduced into a pseudomonas aeruginosa PAO1 cell, an expression strain is successfully constructed, the expression quantity of target protein is improved, efficient expression of LPL in PAO1 is achieved, and the produced LPL is high in enzyme activity and wider in application range.

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.

The invention discloses a method and equipment for detecting oxidized low-density lipoprotein based on immunoturbidimetry, and the method comprises the following steps: preparing a macroinitiator by active esterification reaction, and preparing a block graft copolymer by atom transfer radical polymerization and radical grafting reaction; the preparation method comprises the following steps: carrying out surface modification on latex microspheres with different particle sizes by using a grafted copolymer, and then respectively coupling the microspheres with different particle sizes with different OxLDL monoclonal antibodies so as to prepare a double-particle-size latex microsphere marker; and mixing the serum sample with the double-particle-size latex microsphere marker, measuring an absorbance value, and calculating the concentration of the oxidized low-density lipoprotein in the serum sample according to a standard curve established on the basis of the standard substance solution. According to the scheme, the stability of the latex microsphere marker can be enhanced, and the binding efficiency of the latex microsphere marker and ox-LDL can be improved.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

The invention relates to an application of an Sdccag3 gene in preparation of a weight-reducing medicine for regulating glucose and lipid metabolism. The Sdccag3 gene is used as an action target to be applied to preparation or screening of the weight-reducing medicine for regulating glucose and lipid metabolism, and the nucleotide sequence of the Sdccag3 gene is as shown in SEQ ID No. 1. According to the application disclosed by the invention, the specific overexpressed Sdccag3 in adipose tissues in a mouse body can obviously inhibit the increase of the blood fat level, and the overexpressed Sdccag3 can also obviously improve the poor glucose tolerance, improve the insulin sensitivity, reduce the levels of serum triglyceride, cholesterol and low-density lipoprotein cholesterol of an obese mouse, improve the poor glucose tolerance and improve the insulin sensitivity. The insulin sensitivity is improved, obesity-related glycolipid metabolism is effectively regulated and controlled, the effect of reducing blood lipid and blood sugar is achieved, and the compound can be used for preparing weight-losing drugs for reducing blood lipid and blood sugar.

The present invention provides a lipoprotein subtype detection kit, a preparation method and an application thereof, belonging to the technical field of biological detection. In the separating gel of the kit, BODIPY 505 / 515 is mixed, so that staining is not required during detection, and direct sample loading and electrophoresis can be carried out, reducing the operation steps and shortening the operation time, and improving the detection sensitivity. In addition, N,N'-bisacryloylpiperazine is mixed in both the separating gel and the stacking gel. The rigidity of the N,N'-bisacryloylpiperazine gel is used to reduce gel deformation and trailing phenomena during migration, significantly improving the resolution, and enhancing the stability and repeatability of detection. The detection kit provided by the present invention has the advantages of short detection operation time, high detection sensitivity, high resolution, good stability and repeatability.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

The invention relates to the technical field of biological detection, and discloses an instant staining lipoprotein sample separation method, which comprises the following steps: S1, lipoprotein staining: taking 10 [mu] L of a sample loading staining solution, adding 50 [mu] L of a plasma lipoprotein sample, and completing staining without waiting and heating incubation; s2, sample loading of dyed lipoprotein: assembling a sample density separation liquid pre-loading column in a disc electrophoresis tank, adding an electrophoresis buffer solution, and adding the lipoprotein sample dyed in the step S1 to the upper end of the sample density separation liquid pre-loading column; and S3, electrophoretic separation of the lipoprotein subtypes: switching on a power supply of an electrophoresis apparatus, enabling the lipoprotein with negative charges to migrate to a positive electrode under the action of an electric field, and realizing separation according to different particle sizes of the lipoprotein subtypes. The lipoprotein loading staining solution is good in dispersity and uniformity, and in the preparation process of the lipoprotein loading staining solution, the dye does not need to be filtered to remove insoluble substances and does not need to be heated; the staining solution is good in stability and can be stored at normal temperature.

The invention discloses 4-(pyridine-4-yl)-1H-imidazole-2-amine derivatives and compositions of a machine for assembling key proteins on an outer membrane of targeted gram-negative bacteria, and belongs to the technical field of chemical medicines. The invention provides a small molecule compound as shown in a formula (I): # imgabs0 #, the small molecule compound can be used as a brand new targeting gram-negative bacterium inner membrane lipoprotein positioning machine (LolCDE) and has bacteriostatic activity, and a new way is provided for specific antibacterial treatment of gram-negative bacteria.

The invention discloses a preparation method of an oxidized low-density lipoprotein quality control product prepared on the basis of a novel antigen, and the method comprises the following steps: constructing an oxidized low-density lipoprotein model, carrying out molecular dynamics simulation by setting a plurality of groups of simulation conditions to calculate a stability index, and determining an optimal antigen preparation condition; acquiring antigen epitope data, and constructing a feature vector, so as to predict and screen an optimal antigen epitope by utilizing a machine learning algorithm; and based on a target cross-linking strategy, combining the oxidized low-density lipoprotein prepared under the optimal antigen preparation condition with the optimal epitope to obtain a target quality control product. According to the scheme, the preparation efficiency and quality can be improved.

The invention belongs to the field of microorganisms, and provides lactobacillus paracasei Jlus660321 with a function of assisting in reducing blood fat and cholesterol and application of the lactobacillus paracasei Jlus660321, and the preservation number of the lactobacillus paracasei Jlus660321 is CGMCC No. 33962. The lactobacillus paracasei Jlus 660321 has the functions of assisting in lowering blood fat and lowering cholesterol, shows excellent cholesterol lowering performance in a cholesterol degradation experiment, and can degrade 61.60% of cholesterol in the experiment. A hemolysis experiment result is gamma-hemolysis, namely, hemolysis is avoided, and toxic and side effects are small. Rat in-vivo experiments show that the lactobacillus paracasei Jlus 660321 can effectively slow down the increase of body weight, liver weight, liver index, low-density lipoprotein content and triglyceride content caused by high-fat diet, and further show that the lactobacillus paracasei Jlus 660321 has the function of assisting in reducing blood fat and cholesterol; the compound can be used for preparing medicines, nourishment or health care products for assisting in reducing blood fat and / or reducing cholesterol.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses lactobacillus plantarum YBE2 and application thereof.According to the lactobacillus plantarum YBE2 for high yield of extracellular polysaccharide mainly containing rhamnose, different cholate types can be degraded at the same time, glycocholic acid is specifically hydrolyzed, and the lactobacillus plantarum YBE2 has the effects of lowering cholesterol and relieving acute inflammation at the same time. Meanwhile, the plant lactobacillus YBE2 can reduce the deposition of fat in the belly of the cage rearing broiler chicken, improve intramuscular fat, promote the deposition of fatty acid in muscles, reduce the total bile acid of plasma, triglyceride and low-density lipoprotein cholesterol, and remarkably improve the lipid metabolism and muscle quality of meat poultry, and can be widely applied to the breeding of the cage rearing broiler chicken, promote the healthy breeding of the meat poultry and improve the quality of the meat poultry. The culture benefit is improved.

The invention provides a lipoprotein subtype detection kit as well as a preparation method and application thereof, and belongs to the technical field of biological detection.The separation gel of the kit is mixed with BODIPY 505 / 515, so that dyeing is not needed during detection, direct sample loading electrophoresis can be realized, the operation step flow is reduced, the operation time is shortened, and the detection sensitivity is improved; besides, the N, N-bisacryloyl piperazine is mixed in the separation gel and the concentrated gel, the gel deformation and trailing phenomena in the migration process are reduced by utilizing the rigidity of the N, N-bisacryloyl piperazine gel, the resolution ratio is remarkably improved, and the detection stability and repeatability can be improved; the detection kit provided by the invention has the advantages of short detection operation time, high detection sensitivity, high resolution and good stability and repeatability.

Disclosed herein are polynucleic acid molecules that can be utilized for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3). Also, described herein are pharmaceutical compositions comprising polynucleic acid molecules targeting lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) mRNA. Further provided herein are methods for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) by utilizing the polynucleic acid molecules described herein.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention provides a triglyceride determination kit, the kit comprises a reagent 1 and a reagent 2, the reagent 1 comprises the following main components: piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH 6.8), glycerophosphate oxidase (GPO), peroxidase (POD), triadenosine phosphate (ATP), chromogen, a surfactant, a stabilizer and a preservative; and the reagent 2 comprises the following main components: a piperazine-1, 4-diethyl sulfonic acid (PIPES) buffer solution (pH is 6.5), lipoprotein esterase (LPL), glycerol kinase (GK), 4-aminoantipyrine (4-AA), a surfactant, a stabilizer and a preservative. By optimizing a chromogen substrate in the reagent and adding potassium ferrocyanide, the linear range of the prepared kit is wider, and the bottle opening test is more stable.

Provided are an RNAi agent targeting a lipoprotein (a) (LPA) gene and a use thereof, and more particularly, an RNAi agent comprising an antisense strand having sequence complementarity with an LPA mRNA sequence and a sense strand having sequence complementarity with the antisense strand, and a pharmaceutical composition for preventing or treating cardiovascular diseases comprising the RNAi agent.

A method of evaluating disposition and / or effect of a candidate compound in an in vitro culture and / or suspension to predict in vivo disposition and / or effect of the candidate compound, which can include the steps of providing a cell culture and / or suspension; exposing a candidate compound to the culture and / or suspension; exposing the culture and / or suspension to a media providing an in vivo relevant extracellular environment, such as a media comprising a component (such as a protein and / or other component, such as lipoproteins, bile acids, and endogenous compounds such as bilirubin) at a physiologic concentration or a concentration having characteristics, such as binding characteristics, similar to the physiological concentration; wherein any combination of any of the exposing steps can occur in any order or simultaneously; and evaluating in vitro disposition and / or effect of the compound to predict in vivo disposition and / or effect of the candidate compound.

The invention discloses 4-(1H-pyrazol-4-yl) pyridine derivatives targeting a gram-negative bacteria lipoprotein transport pathway, a composition and application of the 4-(1H-pyrazol-4-yl) pyridine derivatives and belongs to the technical field of chemical medicines. The invention provides 4-(1H-pyrazol-4-yl)-2, 6-dimethyl pyridine and 4-(1H-pyrazol-4-yl) pyridine derivatives with the following structures: # imgabs0 #, the compounds can target a key protein machine of Gram's inner and outer membranes, and have remarkable antibacterial activity; meanwhile, the polypeptide can target key protein machines of gram inner and outer membranes, has good affinity with target protein LolCDE, and provides a new way for specific antibacterial treatment of gram-negative bacteria.

To provide methods for treating an atherosclerotic cardiovascular disease with LPA-targeted RNAi constructs.SOLUTION: The present invention relates to methods for treating or preventing an atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a) being a component of Lp(a) particles. In particular, the present invention relates to methods for reducing serum Lp(a) levels and reducing a risk of cardiovascular events in patients with elevated levels of Lp(a) comprising administering an LPA-targeted RNAi construct according to specific dosage regimens. Further, pharmaceutical compositions containing the LPA-targeted RNAi constructs for use in the methods are also disclosed.SELECTED DRAWING: None

The invention discloses mesenchymal stem cells, a screening and identifying method of lipoprotein particles secreted by the mesenchymal stem cells and application of the mesenchymal stem cells. The screening and identifying method of the mesenchymal stem cells comprises the steps of cell culture, genotype identification, multiplication capacity identification, pluripotency and self-renewal capacity identification, differentiation capacity identification, lipid droplet identification after high fat induction, APOE lipoprotein secretion capacity identification and the like. The screening and identifying method of the lipoprotein particles comprises the steps of high-fat-induced lipoprotein secretion, lipoprotein separation and purification, lipoprotein particle size identification, lipoprotein particle content identification and the like, and target cells and target lipoprotein particles can be rapidly and accurately screened through the systematic screening and identifying method. The screened target lipoprotein particles can improve the dyslipidemia of APOE4 / 4 genotype Alzheimer's disease. Compared with the prior art, the method not only can avoid the gene manipulation risk faced by APOE gene editing, but also can provide a new standard for identification of mesenchymal stem cells and lipoprotein particles secreted by the mesenchymal stem cells, and can screen wider and easier therapeutic cell sources for later application.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The invention discloses a 4E6 antibody-based oxidized low-density lipoprotein detection method, which comprises: obtaining a model constructed by a target 4E6 monoclonal antibody sequence, carrying out docking analysis on the interaction of antigen binding regions, designing a mutant prediction influence, selecting an optimal combination to construct a new sequence, and carrying out expression purification to obtain the oxidized low-density lipoprotein. The optimization effect is verified by measuring and combining kinetic parameters; a dendritic-linear polymer modified structure on the surface of a latex microsphere is designed and optimized based on a computational material science method, and the modified latex microsphere is synthesized and coupled with an optimized 4E6 monoclonal antibody to form a detection probe; and establishing an oxidized low-density lipoprotein standard curve through a plurality of groups of standard substance solutions, and determining a detection limit and a quantitation limit so as to calculate the sample concentration. According to the scheme, the antibody recognition capability and the signal amplification effect can be improved, and the detection sensitivity and accuracy are improved.

The invention discloses a polysaccharide composition for treating hyperlipemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing phellinus linteus linteus, inonotus hispidus and boletus coratus and then performing water extraction. The polysaccharide composition provided by the invention can be used for reducing fat vacuolation and fat index, reducing the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increasing the content of high-density lipoprotein cholesterol by inhibiting the increase of weight and blood sugar of a hyperlipidemia mouse; the composition and abundance of intestinal flora are regulated and controlled, the intestinal flora disorder phenomenon is improved, the effect is better than that of single polysaccharide, and a new direction is provided for treatment for assisting blood sugar reduction.